Logo image of PHIO

PHIO PHARMACEUTICALS CORP (PHIO) Stock Fundamental Analysis

NASDAQ:PHIO - Nasdaq - US71880W5013 - Common Stock - Currency: USD

2.36  -0.04 (-1.67%)

After market: 2.2999 -0.06 (-2.55%)

Fundamental Rating

3

Taking everything into account, PHIO scores 3 out of 10 in our fundamental rating. PHIO was compared to 557 industry peers in the Biotechnology industry. While PHIO seems to be doing ok healthwise, there are quite some concerns on its profitability. PHIO has a valuation in line with the averages, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

PHIO had negative earnings in the past year.
In the past year PHIO has reported a negative cash flow from operations.
In the past 5 years PHIO always reported negative net income.
In the past 5 years PHIO always reported negative operating cash flow.
PHIO Yearly Net Income VS EBIT VS OCF VS FCFPHIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

PHIO has a Return On Assets (-52.08%) which is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of -56.42%, PHIO is in the better half of the industry, outperforming 62.12% of the companies in the same industry.
Industry RankSector Rank
ROA -52.08%
ROE -56.42%
ROIC N/A
ROA(3y)-110.57%
ROA(5y)-88.07%
ROE(3y)-133.23%
ROE(5y)-105.56%
ROIC(3y)N/A
ROIC(5y)N/A
PHIO Yearly ROA, ROE, ROICPHIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PHIO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PHIO Yearly Profit, Operating, Gross MarginsPHIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20K -40K -60K

More info and screens

6

2. Health

2.1 Basic Checks

PHIO has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, PHIO has more shares outstanding
There is no outstanding debt for PHIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
PHIO Yearly Shares OutstandingPHIO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M
PHIO Yearly Total Debt VS Total AssetsPHIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

2.2 Solvency

Based on the Altman-Z score of -11.29, we must say that PHIO is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of PHIO (-11.29) is worse than 76.12% of its industry peers.
PHIO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -11.29
ROIC/WACCN/A
WACCN/A
PHIO Yearly LT Debt VS Equity VS FCFPHIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

A Current Ratio of 10.24 indicates that PHIO has no problem at all paying its short term obligations.
With a decent Current ratio value of 10.24, PHIO is doing good in the industry, outperforming 78.99% of the companies in the same industry.
PHIO has a Quick Ratio of 10.24. This indicates that PHIO is financially healthy and has no problem in meeting its short term obligations.
PHIO's Quick ratio of 10.24 is fine compared to the rest of the industry. PHIO outperforms 78.99% of its industry peers.
Industry RankSector Rank
Current Ratio 10.24
Quick Ratio 10.24
PHIO Yearly Current Assets VS Current LiabilitesPHIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

0

3. Growth

3.1 Past

PHIO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 67.62%, which is quite impressive.
EPS 1Y (TTM)67.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90.31%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y167.69%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PHIO Yearly Revenue VS EstimatesPHIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2023 2025 20M 40M 60M
PHIO Yearly EPS VS EstimatesPHIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2018 2019 2020 2021 2022 2023 2024 2025 0 -100K -200K -300K -400K -500K

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

PHIO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 0.54 indicates a rather cheap valuation of PHIO.
Based on the Price/Forward Earnings ratio, PHIO is valued cheaper than 99.64% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.19, PHIO is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 0.54
PHIO Price Earnings VS Forward Price EarningsPHIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PHIO Per share dataPHIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 -6

4.3 Compensation for Growth

PHIO's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

PHIO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PHIO PHARMACEUTICALS CORP

NASDAQ:PHIO (6/18/2025, 8:18:53 PM)

After market: 2.2999 -0.06 (-2.55%)

2.36

-0.04 (-1.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-07 2025-05-07
Earnings (Next)08-12 2025-08-12
Inst Owners16.78%
Inst Owner Change-45.45%
Ins Owners0.48%
Ins Owner Change2.31%
Market Cap11.33M
Analysts82.86
Price Target4.08 (72.88%)
Short Float %4.75%
Short Ratio0.06
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-87.36%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 0.54
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.97
P/tB 0.97
EV/EBITDA N/A
EPS(TTM)-6.48
EYN/A
EPS(NY)4.39
Fwd EY185.85%
FCF(TTM)-1.33
FCFYN/A
OCF(TTM)-1.33
OCFYN/A
SpS0
BVpS2.44
TBVpS2.44
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -52.08%
ROE -56.42%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-110.57%
ROA(5y)-88.07%
ROE(3y)-133.23%
ROE(5y)-105.56%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.24
Quick Ratio 10.24
Altman-Z -11.29
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)58.99%
Cap/Depr(5y)53.61%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)67.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90.31%
EPS Next Y167.69%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y24.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y43.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y43.89%
OCF growth 3YN/A
OCF growth 5YN/A